Updates are available Correction dated 2024-10-10
Click to view Correction: https://doi.org/10.1038/s41575-024-01007-x
-
Authors
Burra, Patrizia http://orcid.org/0000-0002-8791-191X
Zanetto, Alberto
Schnabl, Bernd
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Montano-Loza, Aldo J. http://orcid.org/0000-0002-2511-7980
Asselta, Rosanna
Karlsen, Tom Hemming http://orcid.org/0000-0002-8289-9931
Tacke, Frank http://orcid.org/0000-0001-6206-0226
- License Information
-
More Information
Article History
Accepted: 25 July 2024
First Online: 5 September 2024
Change Date: 10 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41575-024-01007-x
Competing interests
: P.B. has received lecture and consulting fees from Biotest, Chiesi Farmaceutici and Sandoz. B.S. has been consulting for Ambys Medicines, Ferring Research Institute, Gelesis, HOST Therabiomics, Intercept Pharmaceuticals, Mabwell Therapeutics, Patara Pharmaceuticals, Surrozen and Takeda. B.S. is founder of Nterica Bio. UC San Diego has filed several patents with B.S. as inventor related to this work. B.S.’s institution, UC San Diego, has received research support from Axial Biotherapeutics, BiomX, ChromoLogic, CymaBay Therapeutics, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Prodigy Biotech and Synlogic Operating Company. T.R. received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking honoraria from Abbvie, Gilead, Intercept/Advanz Pharma, Roche, MSD, W. L. Gore & Associates; consulting/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead and Roche. T.H.K. received speaker fees from Gilead and did consulting for Falk Pharma, Albireo, MSD and Boeringer Ingelheim – consulting. F.T.’s laboratory has received research funding from Gilead, AstraZeneca, and MSD (funding to the institution). F.T. has received honoraria for consulting or lectures from AstraZeneca, Gilead, AbbVie, BMS, Boehringer, Madrigal, Intercept, Falk, Inventiva, MSD, GSK, Orphalan, Merz, Pfizer, Alnylam, CSL Behring, Novo Nordisk, Sanofi, and Novartis. A.Z., A.J.M.-L. and R.A. have nothing to disclose.
